Navigation Links
Proteasome activator enhances survival of Huntington's disease neuronal model cells

To function, each living cell needs both to build new and to degrade old or damaged proteins. To accomplish that, a number of intracellular systems work in concert to keep the cell healthy and from clogging up with damaged proteins. When proteins or peptides mutate, they can present major problems to the clearing up of the intracellular environment. In Huntington's disease (HD) the disease provoking mutation in the huntingtin gene eventually causes the cell to build up intranuclear and cellular inclusions of protein-aggregates, made up primarily of huntingtin. One cellular organelle with a central role of clearing such protein build up in the cell is the ubiquitin proteasome system (UPS).

In Huntington's disease (HD) brains and other tissues, UPS activity is inhibited and intraneuronal nuclear protein aggregates of mutant huntingtin in HD brains indicate dysfunction of the UPS. From these results, we hypothesized that enhancing UPS function would improve catalytic degradation of abnormal proteins in HD. We first genetically engineered proteasome activators involved in either non-ubiquitinated protein degradation pathways (PA28ƒ×) or subunits of PA700, the 26S proteasome ubiquitinated pathway (S5a) into transducible lentiviral vectors. To address the therapeutic hypothesis experimentally, we transduced UPS subunits into HD skin fibroblasts or HD mutant protein expressing striatum-derived neurons. We determined how this intervention altered cell survival after exposure to toxins known to simulate pathological mechanisms in HD.

The manuscript shows that cellular changes due to expression of huntingtin protein with longer CAG repeats can reduce the ubiquitin proteasome system (UPS) function in Huntington¡¦s disease cells. Following compromise of the UPS, the overexpression of proteasome activator PA28 can specifically recover proteasome function and improve cell viability in both HD model and patient cells.

These remarkable results demonstrat e for the first time that it is possible to intervene therapeutically in the proteolytic pathways and organelles that participate in the specific degradation of misfolded and abnormal proteins.


Source:Public Library of Science

Related biology news :

1. Pulsating ultrasound enhances gene therapy for tumors
2. Elevated temperature enhances success of viral cancer therapy
3. NYU algorithm enhances ability to detect cancer genes
4. The Bacterias guide to survival
5. Boosting HIV screening can increase survival and is cost effective
6. Researchers identify protein crucial for survival of Lyme-disease bacterium
7. Novel protein complex enables survival in hostile environment
8. BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins
9. UCI researchers discover key factor for survival of human embryonic stem cells
10. Rhinos clinging to survival in the heart of Borneo, despite poaching
11. DNA: Bacterias survival ration
Post Your Comments:

(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today announced ... chief executive officer, will present at the 27 th ... New York City . The presentation will be webcast ... 9:30 a.m. EST. and go to ... 15 minutes prior to the presentation to allow for any ...
(Date:11/24/2015)... 24, 2015 According to two new studies, fewer ... is something that many doctors, scientists, and public health experts ... with fewer PSA tests being done, will there be more ... Dr. David Samadi, "Despite the efforts made in regards ... second leading cancer cause of death in men, killing approximately ...
(Date:11/23/2015)... 23, 2015 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its preliminary unaudited financial results for the second quarter ... 30, 2015. --> --> ... Revenues for the second quarter of fiscal 2016 increased ...
(Date:11/23/2015)... GENEVA , November 23, 2015 ... to develop daclatasvir for 112 ... countries   --> --> ... licence for a hepatitis C medicine, signing an agreement with ... proven to help cure multiple genotypes of the HCV virus. ...
Breaking Biology Technology: